Trials

The effect of low-dose radiotherapy on pain in early osteoarthritis of the hip

Clinically node negative breast cancer patients undergoing breast conserving therapy: sentinel lymph node procedure versus follow-up

Patient satisfaction after oncoplastic breast reconstruction

Exploratory study on nasal high flow therapy for breath hold in radiotherapy

Neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer

Influence of the intestinal microbiome on the outcome of treatment with preoperative chemoradiotherapy in patients with resectable oesophageal carcinoma

Prospective data collection initiative on colorectal cancer

The (cost)effectiveness of neoadjuvant folfirinox versus neoadjuvant gemcitabine based chemoradiotherapy and adjuvant gemcitabine for (borderline) resectable pancreatic cancer

Rectal preserving treatment for early rectal cancer. A multi-centered randomised trial of radical surgery versus adjuvant radiotherapy after local excision for early rectal cancers

Transarterial Chemoembolization with Drug-Eluting Beads (standard arm) versus Stereotactic Body Radiation Therapy (experimental arm) for hepatocellular carcinoma

Developing and validating cancer patient and oncologist measures for realization of shared decision making

Evaluating the applicability of a mobile application in the communication with trial participants and investigating the feasibility and preferences of a mobile application for delivering patient registered outcome measures (PROMs) compared to paper questionnaires

External beam radiochemotherapy and MRI based adaptive BRAchytherapy in locally advanced CErvical cancer

Randomised Phase III Trial of molecular profile-based versus standard recommendations for adjuvant radiotherapy for women with early stage endometrial cancer

A nurse-led sexual rehabilitation programme for women with gynaecological cancers receiving radiotherapy: a randomized multicentre trial

A randomized study with cisplatinum or cetuximab and standard or adaptive high dose radiotherapy for advanced head and neck cancer

Cancer types Head and neck Title of study Evaluation of the impact of a decision aid tool for patients with advanced larynx cancer and assessment of its influence on shared decision making Version Number Approval Date  4.1, 7 November 2017 Short Title LaDecA Study site Principle Investigator J.F. Petersen, MD PhD Investigator Maastro F.J.P. Hoebers,

A dedicated multidisciplinary head and neck cancer rehabilitation program compared to usual supportive care for patients treated with concomitant chemo-radiotherapy: assessment of effectiveness and cost-effectiveness in a multicenter prospective observational study

Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): a randomised controlled trial with dose reduction to the elective neck in head and neck squamous cell carcinoma

Assessing the Effect of Decision Support for Prophylactic Cranial Irradiation (PCI) for Small-Cell Lung Cancer Patients

Elderly with locally advanced Lung cancer: Deciding through geriatric Assessment  on the oPtimal Treatment strategy

Patients continue the same immune therapy they already received and get radiotherapy to one lesion. The lesion may or may not be symptomatic, but it should be a lesion that increased in size, i.e. containing resistant cells, according to RECIST 1.1 criteria. The preferred radiotherapy dose is 24 Gy in 3 fractions (dosage on the 10 Gy isodose is allowed), but other fractionation schedules (e.g. 30 Gy/ 10 fractions, 20 Gy/ 5 fractions, 20-24 Gy / 1 fraction for SRS) are allowed if these are standard for a certain location or palliative indication in the body.

Primary intracranial germ-cell tumours in adults; evaluation and treatment protocol

A randomized, placebo controlled phase 2b/3 study of ABT-414 with concurrent chemoradiation and adjuvant Temozolomide in subjects with newly diagnosed glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1)

Medulloblastoma in Adults Treatment Protocol, Dutch Society for Neuro-Oncology (LWNO)

DOsis REductie van preoperatieve radiotherapie bij het MYxoidLiposarcoom

Cancer types Urology Title of study Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney - A Phase II study Version Number Approval Date  2, 12 December 2018 Short Title Fastrack II Study site Principle Investigator Prof. Shankar Siva Investigator Maastro Dr. B. Vanneste Sponsor MAASTRO Trial registry ClinicalTrials.gov/NCT02613819 Objectives  Primary Objective: The primary objective

A drawback of the standard whole gland brachytherapy for prostate cancer is that large volumes of sensitive organs and structures are irradiated to a high dose. The unavoidable dose on these organs and structures will lead to unwanted late effects. Reducing the irradiated volume for a selected group of patients with unilateral low-risk significant disease can reduce the probability of late effects. The hypothesis in this study is that by performing hemigland brachytherapy the incidence of erectile dysfunction can be reduced by 20%

The impact of the implementation of a decision aid tool for prostate cancer patients on the decision making process